Background
Methods
Analytical framework
Stepwise approach
Country-, regional- and global-level priority setting
Region | Country | No. informants | Method used to define priority policy issues |
---|---|---|---|
Latin America | Dominican Republic | 12 | Ranking during face-to-face interviews or web-based surveys |
Suriname | 12 | ||
El Salvador | 12 | ||
Colombia | 12 | ||
Africa | Cameroon | 102 | Consensus meeting validating analysis of KII |
Congo | 110 | ||
Gabon | 80 | ||
Chad | 110 | ||
Rwanda | 28 | ||
Ghana | 16 | ||
South East Asia | India | 26 | Qualitative analysis of KIIs |
Western Pacific | Cambodia | NA* | NA* |
Lao PDR | 18 | Ranking during face-to-face interviews | |
Vietnam | 21 | Ranking during face-to-face interviews | |
Eastern Mediterranean | Iran | 20 | Ranking meeting |
Pakistan | 21 | Consensus meeting validating analysis of KII | |
Lebanon | 29 | Ranking meeting |
Literature scoping
Literature search strategy
Formulation of research questions and ranking
Results
Policy concerns raised at country-, regional-, and global-level
Priority policy issue | No. of regions | No. of global KII |
---|---|---|
1. Medicine selection and use
| ||
Generic medicines: perceptions of patients, communities, prescribers and dispensers of low quality and efficacy of generic medicines. Inadequate demand for branded medicines, perceived as superior to generics. | 5 | 15 |
Clinical practice guidelines, Standard Treatment Guidelines (STG), National Essential Medicines List (NEML): development, implementation, enforcement, standardization of implementation between public and private sector, procedures for addition and deletion to NEML, STG, formularies, generic policies. Impact of these on medicines use and access. | 5 | 15 |
Health seeking behaviour of patients, households and communities: knowledge and awareness of general public on medicines, patients’ expectations from health services, adherence to prescribed medication and treatment; self-medication. | 5 | 14 |
Overuse of medicines: inappropriate use of injections, intravenous perfusions, antibiotics. | 3 | 20 |
Financial and non-financial incentives for providers: impact of incentives on prescribing practices, quality of care and access. Includes issues related to transparency of incentive systems or the impact of removing financial link between patients and providers. | 3 | 20 |
2. Sustainable financing and affordable prices
| ||
Medicines and health financing arrangements: coverage and reimbursement of medicines under pre-payment and social health insurance schemes, impact on access, out-of-pocket and catastrophic expenditures. Includes resource mobilization for universal coverage of medicines, fragmentation of financing schemes, cost containment policies. | 5 | 18 |
Resource allocation for health and medicines: government budget for health, funds allocated to health service delivery and medicines. Includes issues related to accountability and disbursement of funds at implementation level, and impact of these on medicine availability and prices. | 5 | 18 |
Medicine pricing: pricing policies and regulations, and their impact on access, especially mark-up. Includes issues related to transparency, corruption and speculation on medicine prices. | 5 | 18 |
3. Leadership and governance
| ||
Crosscutting policies outside the health sector affecting health and medicines access: such as finance policies or legal issues, coordination and engagement of stakeholders across sectors, and transparency (e.g., regulation and management of conflicts of interest, regulation of incentives and profits above the health sector). | 4 | 14 |
Governance over the private sector: mapping private sector health service delivery and assessment of training and support needs, governance over the informal pharmaceutical markets, regulation of unethical promotion practices and impact on access. | 4 | 14 |
Donors’ agenda, funding type and funding mechanisms; impact on access. | 3 | 18 |
4. Availability of medicines
| ||
Procurement, supply and stock management: limited capacity for these functions in resource limited settings, including regulatory capacity and enforcement. Includes issues related to regulation and enforcement of generic policy for procurement and supply. | 5 | 9 |
Medicine availability in the public sector: comparison with availability in the private sector, consequences on health seeking behaviour, medicine use, price and affordability. | 4 | 9 |
Geographical accessibility: physical barriers, remoteness, geographical distribution of health services; impact on access. | 3 | 9 |
5. Human resources for health
| ||
Deployment/shortage and training of human resources for health, e.g., in underserved areas; impact on access. | 4 | 20 |
6. Quality of medicines and quality assurance systems
| ||
Counterfeit medicines: regional and national strategies, inspection and border control. | 5 |
NA*
|
Substandard medicines: technical capacity for quality assurance in LMICs, e.g., laboratory capacity, minilabs; regulation of quality standards and enforcement capacity. | 4 | 16 |
7. Medicine information and information systems
| ||
Monitoring and evaluation systems on rational use, price and quality: data collection, flow of information, adequate and timely use by all stakeholders. | 3 | 5 |
Literature scoping
Priority policy issue | No. of articles | Assessing effect | Methods | ||||
---|---|---|---|---|---|---|---|
SRain LMIC (Total # SR) | Quantitative | Qualitative | Mixed | Other | |||
1. Medicine selection and use
| |||||||
Generic medicines | 48 | 6 | 1 (1) | 8 | 23 | 13 | 3 |
Clinical practice guidelines, Standard Treatment Guidelines, National Essential Medicines Lists | 49 | 12 | 4 (4) | 8 | 17 | 17 | 3 |
Health seeking behaviour of patients, households and communities | 33 | 2 | 1 (3) | 2 | 14 | 11 | 3 |
Overuse of medicines | 34 | 4 | 2 (2) | 11 | 12 | 7 | 2 |
Financial and non-financial incentives for providers | 15 | 6 | 1 (4) | 0 | 5 | 4 | 2 |
2. Sustainable financing and affordable prices
| |||||||
Medicine and health financing arrangements | 27 | 12 | 1 (4) | 10 | 3 | 10 | 0 |
Resource allocation for health and medicines | 3 | 1 | 0 (0) | 1 | 00 | 1 | 1 |
Medicine pricing | 41 | 12 | 0 (3) | 19 | 0 | 9 | 10 |
3. Leadership and governance
| |||||||
Cross-cutting policies above the health sector affecting health and medicine access | 12 | 1 | 1 (1) | 0 | 1 | 3 | 7 |
Governance over the private sector | 28 | 4 | 1 (2) | 4 | 14 | 2 | 6 |
Donors agenda, funding type and funding mechanisms | 14 | 10 | 0 (0) | 4 | 3 | 3 | |
4. Availability of medicines
| |||||||
Procurement, supply and stock management | 12 | 2 | 0 (0) | 5 | 4 | 3 | 0 |
Medicine availability in the public sector | 29 | 5 | 1 (2) | 6 | 4 | 14 | 3 |
Geographical accessibility | 16 | 8 | 1 (1) | 5 | 4 | 4 | 2 |
5. Human resources for health
| |||||||
Deployment/shortage and training of human resources for health | 3 | 2 | 0 (0) | 0 | 1 | 2 | 0 |
6. Quality of medicines and quality assurance systems
| |||||||
Counterfeit medicines | 9 | 2 | 3 (3) | 1 | 1 | 2 | 2 |
Substandard medicines | 34 | 9 | 1 (1) | 8 | 12 | 5 | 8 |
7. Medicine information and information systems
| |||||||
Monitoring and evaluation systems on rational use, price and quality | 35 | 4 | 1 (1) | 4 | 11 | 8 | 11 |
Formulation of research questions and ranking
Research questions | Total score | Overall score | Top 5 | Innovation | Impact | Equity | Lack of research |
---|---|---|---|---|---|---|---|
1. In risk protection schemes, which innovations and policies improve equitable access to and appropriate use of medicines, sustainability of the insurance system, and financial impact on insurance members? | 1 | 1 | 1 | 2 | 1 | 2 | 1 |
2. What are the impacts of different resource allocation mechanisms in fragmented or decentralized health or pharmaceutical systems on access to and use of medicines? | 11 | 11 | 14 | 15 | 14 | 8 | 10 |
3. What are the impacts of different pricing policies and strategies on medicine prices, availability and use? | 6 | 3 | 8 | 10 | 11 | 3 | 3 |
4. What is the impact of different strategies on perception and use of quality assured low-cost generic medicines by key stakeholders including patients, prescribers, dispensers, regulators? | 10 | 10 | 10 | 11 | 10 | 10 | 12 |
5. What is the impact of individual or combined strategies, in particular regulation and economic incentives, in implementing Standard Treatment Guidelines or Essential Medicines list, on appropriate use of medicines in the public and private sector? | 15 | 14 | 12 | 16 | 15 | 14 | 15 |
6. Which innovative strategies targeting individuals, households, communities and systems improve appropriate demand (health seeking behaviour) for access and use of essential medicines? | 4 | 8 | 4 | 3 | 4 | 5 | 6 |
7. What are the best ways of optimizing supply chain management and improving transparency using a systems perspective to improve access to medicines? | 16 | 17 | 17 | 12 | 16 | 17 | 16 |
8. What is the effectiveness and cost-effectiveness of interventions that can be used to detect and reduce supply and demand of counterfeit (fake/falsified) medicines? | 13 | 15 | 12 | 9 | 13 | 16 | 9 |
9. How do we understand and intervene in labour markets for pharmaceuticals to improve the quality of and access to essential medicines? | 12 | 13 | 16 | 14 | 9 | 13 | 7 |
10. What are effective strategies to reduce substandard medicine production, to improve medicine quality and regularly disseminate results? | 14 | 12 | 11 | 12 | 12 | 15 | 12 |
11. How do non-health sector policies (e.g., industry, trade and intellectual property, legal and constitutional, civil service, transport, banking, education, defence, financial systems, customs) influence access to and use of medicines? | 5 | 6 | 4 | 4 | 4 | 5 | 4 |
12. How do policies and other interventions into private markets (such as information, subsidies, price controls, donation, regulatory mechanisms, promotion practices, etc.) impact on access to and appropriate use of medicines? | 2 | 2 | 4 | 1 | 3 | 4 | 2 |
13. What are the lessons learned from best practices for public sector management of essential medicine programs to improve access and appropriate use of medicines? | 17 | 15 | 17 | 18 | 17 | 12 | 17 |
14. Based on evidence of impact of inappropriate drug use on burden of disease, drug resistance and systems and household expenditures, how can systems most effectively and sustainably scale up interventions? | 9 | 8 | 8 | 4 | 4 | 9 | 10 |
15. What incentives in a health system optimize prescribing, dispensing and sales practices among the full range of providers (public, private, formal and informal)? | 8 | 4 | 3 | 4 | 4 | 7 | 7 |
16. What are the best practices of donor and NGO behaviour in working with stakeholders, to strengthen capacity of national systems to improve access to and appropriate use of medicines? | 18 | 18 | 14 | 17 | 18 | 18 | 18 |
17. Which innovations effectively improve access (including geographic accessibility, social acceptability, availability, and financial accessibility) of under-served communities to essential medicines, including community engagement strategies? | 3 | 7 | 7 | 8 | 8 | 1 | 12 |
18. How can stakeholders use the information available in the system (e.g., price, availability, quality, utilization, registration, procurement) in a transparent way towards improving access and use of medicines? | 7 | 4 | 2 | 4 | 2 | 10 | 4 |